Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and ⁶⁸Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial

Abstract

Earlier clinical studies reported a high sensitivity of pretargeted immunoscintigraphy using murine or chimeric anticarcinoembryonic antigen (CEA) bispecific antibody (BsMAb) and peptides labeled with 111 In or 131 I in medullary thyroid carcinoma (MTC). Preclinical studies showed that new-generation humanized recombinant anti-CEA · antihistamine-succinyl-glycine (HSG) trivalent BsMAb TF2 and radiolabeled HSG peptide (IMP288) present good features for PET. This study aimed at optimizing molar doses and pretargeting interval of TF2 and 68 Ga-labeled IMP288 for immuno-PET in relapsed MTC patients with calcitonin serum levels greater than 150 pg/mL. Methods: Five cohorts (C1-C5) of 3 patients received variable molar doses of TF2 and approximately 150 MBq of 68 Ga-IMP288 after different pretargeting time intervals (C1: 120 nmol TF2, 6 nmol IMP288, 24 h; C2: 120 nmol TF2, 6 nmol IMP288, 30 h; C3: 120 nmol TF2, 6 nmol IMP288, 42 h; C4: 120 nmol TF2, 3 nmol IMP288, 30 h; and C5: 60 nmol TF2, 3 nmol IMP288, 30 h). TF2 and 68 Ga-IMP288 pharmacokinetics were monitored. Whole-body PET was recorded 60 and 120 min after 68 Ga-IMP288 injection. Tumor maximal SUV (T-SUV max ) and T-SUV max -to-mediastinum blood-pool (MBP) SUV mean ratios (T/ MBP) were determined. Results: In C1, T-SUV max and T/MBP ranged from 4.09 to 8.93 and 1.39 to 3.72 at 60 min and 5.14 to 11.25 and 2.73 to 5.38 at 120 min, respectively. Because of the high MBP, the delay was increased to 30 h in C2, increasing T-SUV max and T/MBP. Further increasing the delay to 42 h in C3 decreased T-SUV max and T/ MBP, showing that 30 h was the most favorable delay. In C4, the TF2-to-peptide mole ratio was increased to 40 (delay 30 h), resulting in high T-SUV max but with higher MBP than in C2. In C5, the molar dose of TF2 was reduced, resulting in lower imaging performance. Pharmacokinetics demonstrated a fast TF2 clearance and a clear relationship between blood activity clearance and the ratio between the molar amount of injected peptide to the molar amount of circulating TF2 at the time of peptide injection. Conclusion: High tumor uptake and contrast can be obtained with pretargeted anti-CEA immuno-PET in relapsed MTC patients, especially using optimized pretargeting parameters: a BsMAb-to-peptide mole ratio of 20 and 30 h pretargeting delay. Medul lary thyroid carcinoma (MTC) is relatively infrequent, accounting for less than 10% of all thyroid cancers (1). After initial surgery, serum calcitonin is still detectable in nearly 20% of patients, suggesting residual disease, and imaging including neck ultrasonography, neck and chest CT, liver contrast-enhanced CT or MRI, and spine and pelvic bone MRI is recommended when serum calcitonin is higher than 150 pg/mL (1,2). With the ability to characterize and quantify cancer molecular processes, 18 F-DOPA or 18 F-FDG PET/CT also show high performance in relapsed MTC patients and great potential as surrogate biomarkers, useful for early response evaluation and prediction of clinical outcome (3-6).MTC is characterized by an ...

miR‐98‐5p promotes apoptosis and inhibits migration and cell growth in papillary thyroid carcinoma through Bax/Caspase‐3 by HMGA2

“…It has low malignant grade. PTC frequently occurs in young women, especially those aged 30‐45 years . About 80% tumors have multiple center, and approximately 1/3 involve the bilateral thyroid glands.…”

“…Thyroid carcinoma can be classified into differentiated and non‐differentiated types according to its histological structure . The differentiated type has accounted for about 90%, which is one of the malignancies with the most rapidly increased morbidity recently . Differentiated carcinoma can be further divided into PTC and follicular thyroid carcinoma (FTC) .…”

“…Most thyroid carcinoma cases derive from follicular epithelial cell . On the other hand, follicular epithelial cell carcinoma includes papillary carcinoma, follicular carcinoma, and undifferentiated carcinoma …”

Site-specific conjugation allows modulation of click reaction stoichiometry for pretargeted SPECT imaging

“…The ability to image with faster decaying radionuclides not only limits patient radiation exposure, but also provides more flexibility in radiotracer chemistry, with potential advantages in manufacturing and isotope costs. Clinical evaluations of pretargeted imaging with bispecific antibodies, 6,7 streptavidin/biotin pretargeting, 8,9 and radiolabeled haptens 10 have yielded encouraging results.…”

PET Imaging for Endocrine Malignancies: From Woe to Go

“…Studies have also shown a high expression of C-X-C chemokine receptor type 4 in normal adrenal cortex and adrenocortical tumors, opening new avenues for imaging these tumors with peptides targeting C-X-C chemokine receptor type 4 ( 68 Ga-pentixafor) and theranostic approaches (17,18). Finally, immuno-PET against carcinoembryonic antigen has also been studied in the evaluation of medullary thyroid cancer, with promising results (19).…”